Venus Concept (VERO) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
24 Dec, 2025Executive summary
Q4 2024 revenue was $15.8 million, down 13% year-over-year, primarily due to a strategic shift from subscription to cash system sales and macroeconomic headwinds; FY24 revenue was $64.8 million, down 15% year-over-year, with over 60% of the decline attributed to the shift away from subscription sales.
U.S. cash system sales grew 27% year-over-year and represented 87% of total U.S. system sales in Q4, reflecting successful execution of the new strategy.
International business is transitioning from direct markets to distributor partnerships, with distributor sales more than doubling year-over-year in Q4 and network expansion in Taiwan, Colombia, and India.
Leadership changes and a new management structure were implemented to support growth and profitability.
Operating loss improved to $6.7 million in Q4 2024 from $7.6 million in Q4 2023; FY24 operating loss was $27.2 million, slightly better than $28.3 million in FY23.
Financial highlights
Q4 2024 total revenue was $15.8 million, down $2.4 million or 13% year-over-year; FY24 revenue was $64.8 million, down 15% year-over-year.
Lease revenue declined 58% year-over-year in Q4, offset by a 10% increase in cash systems revenue and sales of products and services; product systems revenue rose 15% in Q4 but fell 9% for FY24.
Gross profit for Q4 2024 was $10.9 million, down 10% year-over-year; gross margin improved to 69.1% from 66.5% in Q4 2023.
Operating expenses in Q4 2024 declined 11% year-over-year, driven by reductions in G&A, selling/marketing, and R&D.
Net loss attributable to stockholders for Q4 2024 was $8 million ($11.23/share), improved from $11.1 million ($20.14/share) in Q4 2023; FY24 net loss was $47 million ($71.17/share), compared to $37.1 million ($68.11/share) in FY23.
Outlook and guidance
No full-year 2025 financial guidance provided due to ongoing strategic review and lender discussions.
Q1 2025 revenue expected to be at least $14 million.
Management expects business performance to improve versus prior year, with structural changes largely complete.
New body system launch anticipated in early second half of 2025, expected to drive growth.
Latest events from Venus Concept
- Revenue down 17% year-over-year, but debt reduced and margin improved amid ongoing risks.VERO
Q2 20241 Feb 2026 - Q3 2024 revenue fell 15% year-over-year as debt was cut by 54% and losses persisted.VERO
Q3 202414 Jan 2026 - Shelf registration enables up to $30.4M in securities sales for global medical technology expansion.VERO
Registration Filing16 Dec 2025 - Shareholders to vote on director elections, auditor ratification, and key share issuance proposals.VERO
Proxy Filing1 Dec 2025 - Shareholders to vote on director elections, auditor ratification, and major share issuances.VERO
Proxy Filing1 Dec 2025 - Vote sought on a reverse stock split to maintain Nasdaq listing and avoid delisting risk.VERO
Proxy Filing1 Dec 2025 - Vote sought to authorize a reverse stock split to maintain Nasdaq listing and enhance share value.VERO
Proxy Filing1 Dec 2025 - Approval sought for share issuance tied to convertible notes after major debt restructuring.VERO
Proxy Filing1 Dec 2025 - Amended registration statement for a public offering, with auditor consent and executive sign-off.VERO
Registration Filing29 Nov 2025